John M Ketcham
Overview
Explore the profile of John M Ketcham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aloiau A, Bobek B, Pearson K, Cherry K, Smith C, Ketcham J, et al.
J Org Chem
. 2024 Jul;
89(16):11525-11536.
PMID: 39073902
In our drug discovery campaigns to target the oncogenic drivers of cancers, the demand for a chemoselective, stereoselective and economical synthesis of chiral benzylamines drove the development of a catalytic...
2.
Sudhakar N, Yan L, Qiryaqos F, Engstrom L, Laguer J, Calinisan A, et al.
Mol Cancer Ther
. 2024 Jun;
23(10):1418-1430.
PMID: 38904222
KRAS is the most frequently mutated oncogene in human cancer and facilitates uncontrolled growth through hyperactivation of the receptor tyrosine kinase (RTK)/mitogen-activated protein kinase (MAPK) pathway. The Son of Sevenless...
3.
Ketcham J, Harwood S, Aranda R, Aloiau A, Bobek B, Briere D, et al.
J Med Chem
. 2024 Mar;
67(6):4936-4949.
PMID: 38477582
The H1047R mutation of is highly prevalent in breast cancers and other solid tumors. Selectively targeting PI3Kα over PI3Kα is crucial due to the role that PI3Kα plays in normal...
4.
Aloiau A, Bobek B, Caddell Haatveit K, Pearson K, Watkins A, Jones B, et al.
J Org Chem
. 2024 Feb;
89(6):3875-3882.
PMID: 38422508
Chiral amine synthesis remains a significant challenge in accelerating the design cycle of drug discovery programs. A zirconium hydride, due to its high oxophilicity and lower reactivity, gave highly chemo-...
5.
Smith C, Chen D, Christensen J, Coulombe R, Fethiere J, Gunn R, et al.
J Med Chem
. 2023 Dec;
67(1):774-781.
PMID: 38156904
SOS1 and SOS2 are guanine nucleotide exchange factors that mediate RTK-stimulated RAS activation. Selective SOS1:KRAS PPI inhibitors are currently under clinical investigation, whereas there are no reports to date of...
6.
Harwood S, Smith C, Lawson J, Ketcham J
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108538
Within the MAPK/RAS pathway, there exists a plethora of protein-protein interactions (PPIs). For many years, scientists have focused efforts on drugging KRAS and its effectors in hopes to provide much...
7.
Smith C, Kulyk S, Ahmad M, Arkhipova V, Christensen J, Gunn R, et al.
RSC Med Chem
. 2022 Dec;
13(12):1549-1564.
PMID: 36545438
Here we describe the early stages of a fragment-based lead discovery (FBLD) project for a recently elucidated synthetic lethal target, the PRMT5/MTA complex, for the treatment of -deleted cancers. Starting...
8.
Smith C, Aranda R, Christensen J, Engstrom L, Gunn R, Ivetac A, et al.
Bioorg Med Chem
. 2022 Aug;
71:116947.
PMID: 35926325
MRTX1719 is an inhibitor of the PRMT5/MTA complex and recently entered clinical trials for the treatment of MTAP-deleted cancers. MRTX1719 is a class 3 atropisomeric compound that requires a chiral...
9.
Ketcham J, Haling J, Khare S, Bowcut V, Briere D, Burns A, et al.
J Med Chem
. 2022 Jul;
65(14):9678-9690.
PMID: 35833726
SOS1 is one of the major guanine nucleotide exchange factors that regulates the ability of KRAS to cycle through its "on" and "off" states. Disrupting the SOS1:KRAS protein-protein interaction (PPI)...
10.
Smith C, Aranda R, Bobinski T, Briere D, Burns A, Christensen J, et al.
J Med Chem
. 2022 Jan;
65(3):1749-1766.
PMID: 35041419
The PRMT5•MTA complex has recently emerged as a new synthetically lethal drug target for the treatment of -deleted cancers. Here, we report the discovery of development candidate . is a...